Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET

被引:3
作者
Guo, Ning [1 ]
Zhang, Fan [2 ,3 ]
Zhang, Xiaomeng [1 ]
Guo, Jinxia [2 ,3 ]
Lang, Lixin [3 ]
Kiesewetter, Dale O. [3 ]
Niu, Gang [3 ]
Li, Quanzheng [1 ]
Chen, Xiaoyuan [3 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Dept Radiol,Med Sch, Boston, MA 02114 USA
[2] Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Xiamen 361005, Peoples R China
[3] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Dynamic PET; Vascular-disrupting agent; Integrin alpha(v)beta(3); F-18]FPPRGD2; ENDOTHELIAL GROWTH-FACTOR; VEGF(121)/RGEL; ANGIOGENESIS; INHIBITION;
D O I
10.1007/s11307-015-0854-4
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The purpose of this study is to evaluate the early response of tumors to a vascular-disrupting agent (VDA) VEGF(121)/recombinant toxin gelonin (rGel) using dynamic [F-18]FPPRGD2 positron emission tomography (PET) and kinetic parameter estimation. Two tumor xenograft models: U87MG (highly vascularized) and A549 (moderately vascularized), were selected, and both were randomized into treatment and control groups. Sixty-minute dynamic PET scans with [F-18]FPPRGD2 that targets to integrin alpha(v)beta(3) were performed at days 0 (baseline), 1, and 3 since VEGF(121)/rGel treatment started. Dynamic PET-derived binding potential (BPND) and parametric maps were compared with tumor uptake (%ID/g) and the static PET image at 1 h after the tracer administration. The growth of U87MG tumor was obviously delayed upon VEGF(121)/rGel treatment. A549 tumor was not responsive to the same treatment. BPND of treated U87MG tumors decreased significantly at day 1 (p < 0.05), and the difference was more significant at day 3 (p < 0.01), compared with the control group. However, the tracer uptake (%ID/g) derived from static images at 1-h time point did not show significant difference between the treated and control tumors until day 3. Little difference in tracer uptake (%ID/g) or BPND was found between treated and control A549 tumors. Considering the tracer retention in tumor and the slower clearance due to damaged tumor vasculature after treatment, BPND representing the actual specific binding portion appears to be more sensitive and accurate than the semiquantitative parameters (such as %ID/g) derived from static images to assess the early response of tumor to VDA treatment. Quantitative analysis based on dynamic PET with [F-18]FPPRGD2 shows advantages in distinguishing effective from ineffective treatment during the course of VEGF(121)/rGel therapy at early stage and is therefore more sensitive in assessing therapy response than static PET.
引用
收藏
页码:865 / 873
页数:9
相关论文
共 31 条
[1]   Detection of Tumor Response to a Vascular Disrupting Agent by Hyperpolarized 13C Magnetic Resonance Spectroscopy [J].
Bohndiek, Sarah E. ;
Kettunen, Mikko I. ;
Hu, De-en ;
Witney, Timothy H. ;
Kennedy, Brett W. C. ;
Gallagher, Ferdia A. ;
Brindle, Kevin M. .
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (12) :3278-3288
[2]   Multimodality molecular imaging of tumor angiogenesis [J].
Cai, Weibo ;
Chen, Xiaoyuan .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 :113S-128S
[3]  
Cai WB, 2006, J NUCL MED, V47, P2048
[4]   Molecular mechanisms and clinical applications of angiogenesis [J].
Carmeliet, Peter ;
Jain, Rakesh K. .
NATURE, 2011, 473 (7347) :298-307
[5]   Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer [J].
Chatterjee, Sampurna ;
Heukamp, Lukas C. ;
Sioba, Maike ;
Schoettle, Jakob ;
Wieczorek, Caroline ;
Peifer, Martin ;
Frasca, Davide ;
Koker, Mirjam ;
Koenig, Katharina ;
Meder, Lydia ;
Rauh, Daniel ;
Buettner, Reinhard ;
Wolf, Juergen ;
Brekken, Rolf A. ;
Neumaier, Bernd ;
Christofori, Gerhard ;
Thomas, Roman K. ;
Ulrich, Roland T. .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (04) :1732-1740
[6]   Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma [J].
de Boueard, Sophie ;
Herlin, Paulette ;
Christensen, James G. ;
Lemoisson, Edwige ;
Gauduchon, Pascal ;
Raymond, Eric ;
Guillamo, Jean-Sebastien .
NEURO-ONCOLOGY, 2007, 9 (04) :412-423
[7]   Antiangiogenic therapy: impact on invasion, disease progression, and metastasis [J].
Ebos, John M. L. ;
Kerbel, Robert S. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (04) :210-221
[8]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[9]   Vascular endothelial growth factor is essential for corpus luteum angiogenesis [J].
Ferrara, N ;
Chen, H ;
Davis-Smyth, T ;
Gerber, HP ;
Nguyen, TN ;
Peers, D ;
Chisholm, V ;
Hillan, KJ ;
Schwall, RH .
NATURE MEDICINE, 1998, 4 (03) :336-340
[10]   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].
Ferrara, N ;
Hillan, KJ ;
Gerber, HP ;
Novotny, W .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400